IBT INTERIM RESULTS
I am pleased to report an increase in both the net asset value ("NAV") per share and share price of the Company. While newsflow from the unquoted portfolio was quiet following the sale of ESBATech in September 2009, the quoted portfolio performed well to capture the renewed investor interest in the biotechnology sector, particularly benefiting the larger-cap companies.
Published on 8th April 2010
/ibt.ams3.digitaloceanspaces.com%2FScience-background-with-molecule-or-atom-Abstract-structure-for-Science-or-medical-background.jpeg)